Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Fuzeon (T-20) supply

Executive Summary

Roche and Trimeris are setting up 1,200-patient access program for HIV fusion inhibitor Fuzeon (T-20/enfuvirtide) in anticipation of supply constraints at time of launch. The program will commence in September/October and reach its patient cap by March 2003, Roche said. "In the short-term, we do not have the flexibility to increase production beyond our current capacity to meet a potentially higher than initially anticipated demand," Roche said. The companies will file Fuzeon in the third quarter and will receive a "fast-track" review. One estimate for expanded availability would have the company supplying 40,000 patients by end of 2004..

You may also be interested in...



Roche Fuzeon 2003 Production: 15,000-Patient Supply Plus 6-Month Cushion

Roche/Trimeris' 2003 production cap for Fuzeon includes doses for 12,000 to 15,000 patients, in addition to a six-month "safety supply," the companies said during a Dec. 18 analyst call

Roche Fuzeon (T-20) NDA

Roche and Trimeris file NDA for HIV fusion inhibitor Fuzeon (T-20/enfuvirtide) Sept. 17. The companies are establishing a 1,200-patient access program in anticipation of supply constraints (1"The Pink Sheet" Aug. 5, In Brief)...

Vaccine Company CEOs Face Supply Probe In EU

AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel